Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease Post author: Post published:April 25, 2024 Post category:uncategorized Funding represents the first time the foundation has taken an equity position in a breath diagnostics company. You Might Also Like True toll of long COVID may be double that of current estimates, research shows May 27, 2026 Study shows how peptides from nature could combat melanoma drug resistance December 19, 2024 Kidney rhythm mismatch linked to dangerous nighttime high blood pressure September 24, 2026